ASCO updates stage IV NSCLC guidance, adding repotrectinib and zongertinib, with trial-backed dosing and sequencing tips for ...

FDA tentatively OKs cabozantinib capsules for RCC, HCC and epNET, with dose-conversion guidance, error warning and improved ...

The single-arm trial met its primary end point of complete response (CR) at any time, exceeding historic and contemporary ...

An investigator behind gedatolisib's FDA approval discusses the trial data, dosing, and adverse effects shaping HR+/HER2- ...

Dr. Monty Pal discusses the growing importance of quality of life and long-term tolerability when selecting subsequent ...

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 in favor of the IGNYTE study (NCT03767348) supporting the potential accelerated approval of vusolimogene oderparepvec (RP1; ...

July 2026 brought a dense run of FDA activity across breast, lung, bladder, and blood cancers, along with a pancreatic cancer application that moved through review in a matter of ...

Dr. Monty Pal discusses how patient- and disease-specific characteristics influence treatment sequencing decisions for advanced renal cell carcinoma (RCC) beyond the first-line setting.

The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Incorporating tucatinib into HP maintenance more than doubled PFS in patients with brain metastases, addressing limited blood–brain barrier penetration of many HER2-directed antibodies. Outside the ...

FDA fast-tracks ISM6331 for hard-to-treat pleural mesothelioma, spotlighting Hippo pathway targeting and early phase 1 results presented at ESMO 2026. The FDA has granted fast track designation to ...

Real-world outcomes were broadly concordant with DESTINY-Lung01/02 efficacy despite inclusion of poorer-performance-status patients and those with active brain metastases typically excluded from ...